Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma

Neurology India

Volumn 62, Issue 1, 2014, Pages 42-47

  Takeuchi, Satoru ^a   Wada, Kojiro ^a   Nagatani, Kimihiro ^a   Otani, Naoki ^a   Osada, Hideo ^a   Nawashiro, Hiroshi ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Tokorozawa Loyal Hospital   (Japan)

Author keywords

Glioblastoma; seizure; side effects; sulfasalazine; X ray computed tomography

Indexed keywords

SALAZOSULFAPYRIDINE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SEIZURE FREE SURVIVAL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84896916421     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.128280     Document Type: Article

References (30)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
4. Kaba SE, Kyritsis AP. Recognition and management of gliomas. Drugs 1997;53:235-44.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
6. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 2002;96:909-17.
7. Ansari SA, Safak M, Del Valle L, Enam S, Amini S, Khalili K. Cell cycle regulation of NF-kappa b-binding activity in cells from human glioblastomas. Exp Cell Res 2001;265:221-33.
8. Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, et al. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 2004;10:5595-603.
9. Robe PA, Nguyen-Khac MT, Lambert F, Lechanteur C, Jolois O, Ernst-Gengoux P, et al. Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol 2007;30:283-90.
10. Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999;59:4383-91.
11. Savaskan NE, Eyupoglu IY. xCT modulation in gliomas: Relevance to energy metabolism and tumor microenvironment normalization. Ann Anat 2010;192:309-13.
12. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 2005;25:7101-10.
13. Lo M, Wang YZ, Gout PW. The x(c)-cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. J Cell Physiol 2008;215:593-602.
14. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 2009;28:599-609.
15. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 2005;65:7446-54.
16. Takeuchi S, Wada K, Toyooka T, Shinomiya N, Shimazaki H, Nakanishi K, et al. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery 2013;72:33-41.
17. Farr M, Tunn EJ, Symmons DP, Scott DG, Bacon PA. Sulphasalazine in rheumatoid arthritis: Haematological problems and changes in haematological indices associated with therapy. Br J Rheumatol 1989;28:134-8.
18. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, et al. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 2009;9:372.
19. Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien) 2000;142:1-15.
20. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995;52:717-24.
21. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-93.
22. Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A. Long-Term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 2009;111:282-92.
23. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993;341:1607-10.
24. Patt S, Steenbeck J, Hochstetter A, Kraft R, Huonker R, Haueisen J, et al. Source localization and possible causes of interictal epileptic activity in tumor-Associated epilepsy. Neurobiol Dis 2000;7:260-9.
25. Senner V, Köhling R, Puttmann-Cyrus S, Straub H, Paulus W, Speckmann EJ. A new neurophysiological/neuropathological ex vivo model localizes the origin of glioma-Associated epileptogenesis in the invasion area. Acta Neuropathol 2004;107:1-7.
26. Köhling R, Senner V, Paulus W, Speckmann EJ. Epileptiform activity preferentially arises outside tumor invasion zone in glioma xenotransplants. Neurobiol Dis 2006;22:64-75.
27. Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ. In vivo assessment of high-grade glioma biochemistry using microdialysis: A study of energy-related molecules, growth factors and cytokines. J Neurooncol 2010;97:11-23.
28. Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med 2011;17:1269-74.
29. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007. p. 33-49.
30. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.